Tracey Beth Hoeg's Departure Sparks FDA Leadership Shake-Up

Acting head of FDA's drug center, Tracey Beth Hoeg, is set to depart amid significant changes in the health department. Hoeg, involved in revising the childhood vaccination schedule, leaves as the White House increases its control over health policies ahead of the midterms.

Tracey Beth Hoeg, the acting chief of the FDA's drug center, is reportedly on her way out just days after the agency's Commissioner Marty Makary resigned, according to insiders.

Hoeg, with her background in epidemiology and sports medicine, played a critical role in revamping the U.S. childhood vaccination schedule earlier this year, reducing the recommended shots from 17 to 11. However, these changes are on hold amidst a lawsuit challenging vaccine policy overhauls under Health Secretary Robert F. Kennedy.

While speculation runs high, Health and Human Services remains tight-lipped on Hoeg's expected departure. This move is a part of a broader strategy, marked by increased White House influence over health policy amid concerns that Kennedy's vaccine reform efforts may affect voter sentiment in the upcoming midterm elections.